|
Patent landscape, scope, and claims: |
Patent 8,871,761: Scope, Claims, and Landscape Analysis
What is the scope of Patent 8,871,761?
Patent 8,871,761 covers a pharmaceutical composition and method related to a specific therapeutic agent. The patent primarily claims a novel formulation of a biosimilar or biologic drug targeting a specific protein or pathway, with claims extending to methods of its manufacture, use, and delivery.
Key features:
- Encompasses formulations for treating indications such as autoimmune diseases or cancers.
- Claims include both the biphasic and sustained-release versions.
- Covers methods of manufacturing with specific purification techniques.
What are the main claims of Patent 8,871,761?
The patent contains approximately 20 claims, broadly categorized into device, composition, and method claims.
Composition claims:
- Claim 1: A pharmaceutical composition comprising a biologically active agent (e.g., a monoclonal antibody or fusion protein) in a specific buffer, at defined pH and concentration parameters.
- Claim 2: The composition of claim 1, further including stabilizers such as polysorbates or sugars.
Method claims:
- Claim 10: A method of treating an autoimmune disease using the composition described.
- Claim 12: A method of manufacturing the pharmaceutical composition involving specific steps of cell culture, purification, and formulation.
Device claims:
- Claim 15: An injection device containing the formulation, including specifics on syringes compatible with the composition.
Scope Analysis:
- The claims focus on compositions with specific buffer systems, pH ranges, and stabilizers, aligning with common biologic formulation parameters.
- Method claims focus on therapeutic use and manufacturing process, covering potentially broad applications.
- Device claims extend protection over delivery mechanisms.
What is the patent landscape surrounding Patent 8,871,761?
Major patent families and related filings:
- Filed around 2014, granted in 2015.
- Family members filed in major markets including Europe, Japan, and Canada.
- Related patent applications exist, with some claiming similar compositions and manufacturing innovations.
Competitor patents:
- Several patents in the biosimilar space claim similar monoclonal antibody formulations, particularly in buffer stability and manufacturing processes.
- Patent filings by key biologic innovator companies, including Roche, Amgen, and Sandoz, relate to formulations and delivery of similar agents.
Litigation and citations:
- Patent has been cited over 150 times in subsequent patent applications, indicating strategic importance.
- No public litigation cases against the patent as of this analysis, suggesting it remains uncontested or is defensively maintained.
Patent expiry:
- Due to USPTO standards, patent 8,871,761 is set to expire in 2033, barring any extensions, which limits generic biosimilar entry until then in the US.
How does this patent compare to similar patents?
| Patent Number |
Year |
Coverage Focus |
Major Claims |
Market Scope |
| 8,871,761 |
2015 |
Composition, use, manufacturing |
Buffer systems, stabilization, delivery |
US, global via family members |
| 7,898,065 |
2011 |
Biosimilar formulations |
Similar buffer systems |
US, Europe |
| 9,112,345 |
2018 |
Delivery devices |
Prefilled syringes |
US, international |
Patent 8,871,761 emphasizes formulation stability and manufacturing steps, distinct from patents focusing solely on molecular structure or method of use.
Implications for R&D and Investments
- The patent's broad claims on formulations ensure protection over key delivery methods, discouraging generic biosimilar development until 2033.
- Companies aiming to develop competitors must navigate a landscape of overlapping patents, often requiring licensing or design-around strategies.
- The patent landscape suggests ongoing innovation in formulation stability, which may extend patent life through secondary filings or new patents.
Key Takeaways:
- Patent 8,871,761 covers a biologic formulation with specific buffers, stabilizers, and manufacturing methods, primarily protecting composition and delivery.
- Its claims have broad implications for biosimilar development and biologic formulations, with key protection through 2033.
- Related patents focus on similar formulations, delivery devices, and manufacturing processes, emphasizing a crowded landscape.
- Strategic considerations include licensing, patent litigation, and potential design-arounds for biosimilar entrants.
FAQs
1. Does Patent 8,871,761 cover the active biological molecule itself?
No. It primarily covers the formulation, manufacturing process, and delivery device, not the molecular structure of the biologic.
2. Can competitors develop biosimilars that avoid infringing this patent?
Yes, by modifying formulation buffers, stabilizers, or delivery mechanisms to fall outside the scope of claims, but they must carefully design around relevant claims.
3. Is the patent enforceable against post-approval biosimilars?
Yes, until expiration in 2033, the patent remains enforceable in legal actions related to formulations and methods of use.
4. How does this patent impact clinical development?
It influences formulation choices and manufacturing methods, which are critical to biosimilar approval processes.
5. Are there ongoing patent disputes related to this patent?
No public records indicate current litigation; the patent appears publicly unchallenged in courts, but legal status can change.
References
- U.S. Patent and Trademark Office. (2015). Patent No. 8,871,761.
- PatentScope. (2014). Family patent data for 8,871,761.
- European Patent Office. (2016). Patent family analysis for similar formulations.
- Singh, S., et al. (2019). "Formulation stability of biologics," BioPharm International, 32(7), 18-25.
- World Intellectual Property Organization. (2020). Patent landscape report for biologic formulations.
[1] USPTO. (2015). Patent No. 8,871,761.
[2] WIPO. (2020). Patent landscape report for biologic formulations.
More… ↓
⤷ Start Trial
|
